CryoPort (CYRX) vs MoonLake Immunotherapeutics (MLTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CryoPort (CYRX) has outperformed MoonLake Immunotherapeutics (MLTX) over the past year, gaining 77.0% versus a gain of 16.1%. Over five years, MLTX leads with a +8.6% price change compared with -75.3% for CYRX. MoonLake Immunotherapeutics is the larger company by market cap ($861.3 million vs $853.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CYRX | MLTX |
|---|---|---|
| Share price | $16.85 | $10.12 |
| Market cap | $853.44M | $861.29M |
| 1-day change | -2.88% | -6.03% |
| YTD return | +80.73% | -18.29% |
| 1-year return | +77.04% | +16.06% |
| 5-year return | -75.31% | +8.57% |
| EPS (TTM) | $-0.81 | $-3.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.36 | $23.29 |
| 52-week low | $7.61 | $8.80 |
| Distance from 52-week high | -8.22% | -56.55% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +16.74% | +182.01% |
| Average volume | 632.63K | 1.44M |
| Shares outstanding | 50.65M | 85.11M |
| Employees | 684 | 130 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CYRX has outperformed MLTX by 61.0 percentage points over the past year.
About CryoPort
CYRX stock →Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 684 employees
About MoonLake Immunotherapeutics
MLTX stock →MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees
CYRX vs MLTX FAQ
Which is bigger, CryoPort or MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics (MLTX) is larger, with a market capitalization of $861.29M compared with $853.44M for CryoPort (CYRX).
Which stock has performed better over the past year, CYRX or MLTX?
CYRX returned +77.04% over the past 12 months, compared with +16.06% for MLTX (price return, excluding dividends). Past performance does not predict future results.
Are CryoPort and MoonLake Immunotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.